Public Citizen says US FDA should immediately pull Eisai and Pfizer's high-dose Aricept from market
US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator Japan’s Eisai (TYO: 4532) and US drugs behemoth Pfizer (NYSE: PFE) and used to treat moderate or severe cases of Alzheimer’s disease, to be removed from the market immediately because of its risk of serious adverse effects and its lack of effectiveness. In a petition filed yesterday with the US Food and Drug Administration the advocacy group was joined by an eminent geriatrician from Johns Hopkins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze